Who is sponsoring NCT04235946?

NCT04235946 is sponsored by Institut Paoli-Calmettes.

What drugs are being tested in NCT04235946?

Interventions in NCT04235946: accompanied and adapted water polo program.

What condition does NCT04235946 study?

NCT04235946 studies Cancer Related Fatigue, Breast Cancer.

Is NCT04235946 still recruiting?

NCT04235946 is currently status unknown. Last updated 19 August 2020.

Last reviewed 2020-08-19 · How we verify

NCT04235946: AQUA-POLO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility Study of an Adapted and Supported Water Polo Program to Reduce Fatigue Related to Cancer and Improve Psychological and Social Recovery in Patients With Breast Cancer Remission

Status unknown NA Last updated 19 August 2020

What this trial tests

NA trial testing accompanied and adapted water polo program in Cancer Related Fatigue in 24 participants. Status unknown.

Timeline

15 March 2021

Primary endpoint
15 December 2021

31 December 2021

Quick facts

Lead sponsor	Institut Paoli-Calmettes
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	24
Start date	15 March 2021
Primary completion	15 December 2021
Estimated completion	31 December 2021
Sites	1 location across France

Drugs / interventions tested

accompanied and adapted water polo program

Conditions studied

Cancer Related Fatigue — all drugs for Cancer Related Fatigue →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

Institut Paoli-Calmettes — full company profile →

Who can join

18 and older, female only, with Cancer Related Fatigue or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of the study is to assess the feasibility of a coached physical activity program in the form of an accompanied and adapted water polo program by evaluating the interest aroused in patients for this proposal. treatments (number of participants and sessions performed).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Aqua polo: Preliminary feasibility and efficacy study of a programme of adapted, supervised water polo to reduce fatigue and improve women's psychological and social recovery after breast cancer treatment: A mixed-methods design.
Cuvelier S, Goetgheluck-Villaron C, Cohen M, Tallet A, et al · · 2023 · cited 2× · PMID 37026030 · DOI 10.1016/j.conctc.2023.101120

Verify or expand the search:

Other recruiting trials for Cancer Related Fatigue

Currently open trials in the same condition.

NCT03773003 — Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS/ME) · NA · recruiting

Other Institut Paoli-Calmettes trials

Trials by the same sponsor.

NCT07461142 — Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers · NA · not yet recruiting
NCT06557421 — De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients · Phase 2 · recruiting
NCT06046794 — Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients · NA · recruiting
NCT06055621 — Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE · Phase 2 · recruiting
NCT05986071 — I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04235946 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Paoli-Calmettes
Last refreshed: 19 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04235946.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing